Blood test call for people potentially impacted by cancer-causing chemicals in the ground

A palpable sense of urgency and frustration is mounting within communities across Wales, particularly those living near or having worked at former industrial sites suspected of harbouring cancer-causing chemicals. Amidst a fervent "clamouring" for answers and accountability, an unnamed advocate voiced a profound hope that public health authorities would "revise their position" regarding mass blood testing for residents potentially exposed to these hazardous substances, primarily polychlorinated biphenyls (PCBs). This sentiment underscores a deep-seated belief among affected populations that individual health monitoring is a crucial step in understanding the true scope of contamination and its impact.

The call for blood testing has found significant support from academic experts. Dr. Dave Megson, an environmental chemist from Manchester Metropolitan University, who was actively involved in the testing featured in the "Buried" documentary, highlighted a concerning disparity between the United Kingdom and other developed nations. He argued that the US and several European countries are considerably more advanced in deploying blood testing methodologies to assess alleged chemical contamination in human populations. Dr. Megson passionately contended that while such tests might not definitively prove that specific cancers or other health conditions were directly caused by PCB exposure, they could still yield invaluable insights. "There’s so much information that we can pull out if you use those non-standard tests and do some advanced science," he stated, suggesting that sophisticated biomarker analysis could reveal patterns of exposure and biological responses that are currently overlooked. PCBs, once widely used in electrical equipment, hydraulic fluids, and various industrial applications due to their non-flammability and stability, are now recognized as persistent organic pollutants with serious health implications, including probable carcinogenicity, endocrine disruption, neurotoxicity, and reproductive harm. Their long half-life means they persist in the environment and bioaccumulate in the food chain, posing a long-term risk to human health.

However, Public Health Wales (PHW), the national public health institute for Wales, has maintained a steadfast refusal to endorse mass blood testing, acknowledging that this stance presents a "difficult message" to concerned communities. Professor Sarah Jones, a consultant in environmental public health at PHW, articulated the health authority’s position, stating: "We appreciate that the communities are worried and that is understandable, but the testing isn’t necessarily going to give any good answers." Her argument centers on the practical limitations and potential negative consequences of such a testing regime.

Professor Jones explained that a fundamental principle of public health intervention is the ability to "put things right for people" once a problem is identified. In the case of PCBs, she highlighted several critical "unknowns" that complicate the utility of blood testing. Firstly, while the toxicity of PCBs is established, the precise dose-response relationship for chronic, low-level environmental exposures, especially in diverse populations with varying genetic predispositions and lifestyles, remains complex and often difficult to interpret definitively at an individual level. Secondly, and perhaps most crucially, there is currently no specific medical treatment or intervention for individuals found to have elevated levels of PCBs in their blood.

"All we could do is give [people] a number that we can’t really interpret and then we can’t make right," Professor Jones elaborated. She expressed profound concern that providing individuals with a potentially alarming "number" – indicating the presence of PCBs – without a clear clinical pathway for intervention or treatment could inadvertently "create even more worry," which she defined as "a health harm in itself." This ethical dilemma underscores the public health authority’s responsibility to weigh the potential benefits of information against the psychological burden it might impose. "There is nothing that blood testing can do that would magically take those worries away – it would only potentially magnify them," Jones concluded, emphasizing that without actionable medical advice, the testing could exacerbate anxiety rather than alleviate it. When directly asked whether the considerable cost of implementing a widespread blood testing regime was a factor in their decision, Professor Jones unequivocally stated: "No… this is not about money." This reassurance aimed to counter any perception that financial constraints were prioritised over public well-being.

Instead of individual blood testing, Professor Jones argued that public authorities should concentrate their efforts on taking "whatever steps need to be taken to make these [suspected dumpsites] as safe as possible." This alternative strategy focuses on source control and preventing further exposure through environmental remediation. This could involve identifying all contaminated sites, conducting thorough risk assessments, implementing containment measures (such as capping or barriers), treating contaminated soil or water, and establishing long-term monitoring programs. The goal is to eliminate or significantly reduce the pathways of exposure for current and future generations, thereby addressing the root cause of the potential health risks.

The concerns emanating from these communities also highlight a growing need for enhanced support within the primary care sector. Dr. Will Mackintosh, from the Royal College of GPs Cymru, acknowledged the significant role general practitioners play as the frontline of healthcare. He suggested that it may be necessary to provide "additional support" for GPs in communities where concerns about alleged chemical contamination have been raised. "It’s clearly something which obviously large numbers of people are concerned about, and general practice has a role in responding to that as best as we can," he stated. This support could encompass specific training on environmental health issues, access to specialist advice, and resources to help GPs effectively communicate with and support anxious patients, potentially including mental health services to manage contamination-related stress and worry.

In response to the growing public concern, the Welsh government has affirmed its commitment to tackling the pervasive issue of contaminated land, declaring it a "key priority." This acknowledgement signals a strategic shift towards proactively addressing the legacy of industrial pollution that scars many parts of Wales. The government announced its intention to "develop a Wales-wide strategy to progressively restore post-industrial land so that communities are no longer exposed to potential risks." Such a comprehensive strategy would likely involve a multi-faceted approach, including:

1. Identification and Prioritisation: Systematically locating and assessing all contaminated sites across the country.
2. Risk Management: Developing frameworks for evaluating the risks posed by different contaminants and sites.
3. Remediation and Restoration: Implementing effective and sustainable cleanup technologies and land restoration practices.
4. Public Engagement: Ensuring transparent communication with affected communities and involving them in decision-making processes.
5. Funding Mechanisms: Establishing robust financial models to support the extensive work required.

Crucially, the Welsh government also stated its intention to strengthen the "polluter pays principle." This foundational environmental policy dictates that those responsible for causing pollution should bear the costs of its cleanup and remediation. By reinforcing this principle, the government aims to ensure environmental justice, holding companies accountable for historical damage and incentivizing responsible industrial practices in the future. Furthermore, recognizing the potentially vast scale and cost of remediation efforts, the Welsh government confirmed it would "continue to press for environmental justice by raising the importance of seeking UK government funding direct with the UK Treasury." This indicates an understanding that addressing decades of industrial legacy may require significant financial investment beyond the devolved budget, necessitating support from the central UK government.

The challenge of accountability is further complicated by the corporate landscape. The original manufacturer of many PCBs, Monsanto, no longer exists in its historical form, having undergone mergers and acquisitions. Eastman Chemical Company, which is responsible for the firm’s legacy production in the UK, has notably not responded to BBC Wales’ repeated requests for comment. This lack of engagement from successor companies exacerbates the sense of injustice felt by communities, making it difficult to assign direct responsibility and secure reparations or contributions towards remediation efforts, further highlighting the complexities of addressing historical environmental damage.

In essence, the debate over blood testing encapsulates a wider tension between individual concerns for health data and public health approaches focused on population-level risk reduction and environmental remediation. While communities yearn for personal answers and reassurance, public health authorities grapple with the ethical implications of providing information without a clear clinical benefit, potentially increasing anxiety. The Welsh government’s commitment to a national strategy for contaminated land and strengthening the "polluter pays principle" offers a path forward for addressing the root causes of exposure, but the demand for individual health monitoring, particularly for persistent and hazardous chemicals like PCBs, is likely to remain a contentious and deeply felt issue for those living in the shadow of industrial legacy.